Proteomics International Laboratories (ASX:PIQ) launched its PromarkerD blood test at the 85th Scientific Sessions of the American Diabetes Association in Illinois, according to a Friday filing with the Australian bourse.
The diagnostic tool is designed to predict the onset of diabetic kidney disease up to four years in advance in individuals with type 2 diabetes, the filing said.
The test, initially available in California, will be provided by the company's Clinical Laboratory Improvement Amendment-certified reference laboratory, per the filing.